GigaGen commences Phase I clinical trial of GIGA-2339 for hepatitis B treatment
The potency of GIGA-2339 is claimed to be more than 2,000 times greater than that of plasma-derived HBV treatments.
Microplate Reader Market Set to Surge at 7.0% CAGR, to Reach USD 843.4 million by 2031 | Transparency Market Research, Inc.
The requirement for high-throughput screening in genomics and drug discovery, as well as increased demand in life sciences ...